Follow
Manuel Domine
Manuel Domine
Associate Head Oncology. Fundación Jiménez Díaz. IIS - FJD. Head Thoracic Oncology & Clinical Trials
Verified email at fjd.es
Title
Cited by
Cited by
Year
Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer
M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ...
New England Journal of Medicine 375 (19), 1823-1833, 2016
96672016
Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer
J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ...
New England Journal of Medicine 373 (2), 123-135, 2015
89622015
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre …
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
The lancet oncology 13 (3), 239-246, 2012
60232012
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
L Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban, E Felip, ...
New England journal of medicine 378 (22), 2078-2092, 2018
58362018
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
MA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ...
New England Journal of Medicine 378 (24), 2288-2301, 2018
34382018
Screening for epidermal growth factor receptor mutations in lung cancer
R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ...
New England Journal of Medicine 361 (10), 958-967, 2009
29772009
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label …
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet 394 (10212), 1929-1939, 2019
16032019
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ...
New England Journal of Medicine 383 (18), 1711-1723, 2020
14252020
Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer
RVN Lord, J Brabender, D Gandara, V Alberola, C Camps, M Domine, ...
Clinical Cancer Research 8 (7), 2286-2291, 2002
9962002
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer
S Gadgeel, D Rodríguez-Abreu, G Speranza, E Esteban, E Felip, ...
Journal of clinical oncology 38 (14), 1505-1517, 2020
9452020
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
AT Shaw, TM Bauer, F de Marinis, E Felip, Y Goto, G Liu, J Mazieres, ...
New England Journal of Medicine 383 (21), 2018-2029, 2020
7982020
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non–small-cell lung cancer
M Cobo, D Isla, B Massuti, A Montes, JM Sanchez, M Provencio, ...
Journal of clinical oncology 25 (19), 2747-2754, 2007
6682007
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ...
The Lancet Oncology 21 (11), 1413-1422, 2020
6422020
Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as …
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
Lancet Oncol 13 (3), 239-246, 2012
6012012
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
EE Vokes, N Ready, E Felip, L Horn, MA Burgio, SJ Antonia, OA Frontera, ...
Annals of oncology 29 (4), 959-965, 2018
4622018
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN …
JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet Oncology 22 (1), 51-65, 2021
4602021
Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer
H Borghaei, S Gettinger, EE Vokes, LQM Chow, MA Burgio, ...
Journal of Clinical Oncology 39 (7), 723-733, 2021
4402021
Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
D Isla, C Sarries, R Rosell, G Alonso, M Domine, M Taron, ...
Annals of oncology 15 (8), 1194-1203, 2004
3912004
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer
J von Pawel, R Jotte, DR Spigel, MER O'Brien, MA Socinski, J Mezger, ...
Journal of clinical oncology 32 (35), 4012-4019, 2014
3592014
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D Rodríguez-Abreu, SF Powell, MJ Hochmair, S Gadgeel, E Esteban, ...
Annals of Oncology 32 (7), 881-895, 2021
3492021
The system can't perform the operation now. Try again later.
Articles 1–20